Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-administration of CoronaVac and Inlive in Children
NCT04993365Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of coronavac and enterovirus 71 vaccine (vero cell), inactivated in coronavirus disease 2019 (COVID-19) and HIV-associated central nervous system involvement (HAND) (2 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Seroconversion rate of the neutralizing antibody to live SARS-CoV-2 and Seroconversion rate of the neutralizing antibody to EV71. Started Nov 2021; status: completed.
02
Drugs
coronavacenterovirus 71 vaccine (vero cell), inactivated
03
Conditions
coronavirus disease 2019 (COVID-19)HIV-associated central nervous system involvement (HAND)
Beyond the preview
Go deeper on NCT04993365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993365.